H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

Company Overview

H. Lundbeck A/S is a Denmark-based pharmaceutical company specializing in the research, development and commercialization of therapies for central nervous system (CNS) disorders. Founded in 1915 by Hans Christian Lundbeck, the company has grown from a small chemical wholesaler into a global leader in neurology and psychiatry. Its product portfolio spans treatments for depression, anxiety, schizophrenia, Alzheimer’s disease, Parkinson’s disease and rare neurological conditions, and includes market-leading brands such as Cipralex/Lexapro (escitalopram) and Northera (droxidopa).

Over the decades, Lundbeck has established a strong presence across Europe, North America, Latin America and the Asia-Pacific region. The company’s manufacturing sites in Denmark, France and Italy support large-scale production of both small-molecule and biologic therapies, while research and development facilities in Copenhagen and New Jersey drive innovation in CNS drug discovery. Strategic partnerships and in-licensing agreements have further enriched its pipeline, notably collaborations on long-acting injectable antipsychotics and novel agents for migraine and movement disorders.

In recent years, Lundbeck has expanded its R&D focus through acquisitions and internal growth initiatives. The acquisition of specialized biotech firms has bolstered its expertise in neurodegenerative disease and rare CNS conditions, and its late-stage pipeline features candidates targeting treatment-resistant depression, cognitive impairment in schizophrenia and neuroinflammation. The company’s translational research efforts leverage advanced neuroscience platforms, biomarkers and patient-centric clinical trial designs to accelerate time to market.

Leadership at Lundbeck emphasizes scientific excellence, patient access and sustainable growth. Under the stewardship of President and CEO Deborah Dunsire, the company pursues a patient-first strategy, aiming to improve lives through innovative therapies and global outreach programs. Supported by a board of directors with diverse expertise in life sciences and healthcare, Lundbeck continues to strengthen its position as a specialist pharmaco-therapeutics company dedicated to addressing unmet needs in CNS health.

Key Stats

• Today's Range: $22.00 to $24.00
• 50-Day Range: $22.00 to $22.00
• 52-Week Range: $10.00 to $31.55
• Volume: 7,500 shs
• Average Volume: 1,758 shs
• Market Capitalization: $21.91 billion
• P/E Ratio: 25.00
• Dividend Yield: 0.91%
• Price Target: N/A
• Consensus Rating: N/A

HLUYY Stock Analysis - Frequently Asked Questions

How have HLUYY shares performed this year?

H. Lundbeck A/S's stock was trading at $22.00 on January 1st, 2025. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00.

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) posted its earnings results on Wednesday, November, 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.16. The firm had revenue of $547.05 million for the quarter, compared to the consensus estimate of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%.

Does H. Lundbeck A/S have any subsidiaries?

The following companies are subsidiaries of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/04/2015
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private Households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HLUYY
• CIK: N/A
• Web: www.lundbeck.com
• Phone: (453) 630-1311
• Fax: 45-3630-1940
• Employees: 5,348
• Year Founded: 1915

Profitability

• EPS (Trailing Twelve Months): $0.88
• Trailing P/E Ratio: 25.00
• Forward P/E Ratio: 10.48
• P/E Growth: N/A
• Net Income: $209.69 million
• Net Margins: 6.74%
• Pretax Margin: 7.83%
• Return on Equity: 13.74%
• Return on Assets: 7.16%

Debt

• Debt-to-Equity Ratio: 0.32
• Current Ratio: 1.15
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $2.59 billion
• Price / Sales: 8.45
• Cash Flow: $3.36 per share
• Price / Cash Flow: 6.54
• Book Value: $14.60 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 995,741,000
• Free Float: N/A
• Market Cap: $21.91 billion
• Optionable: Not Optionable
• Beta: 0.68